Kardium developed the Globe® Pulsed Field System, a catheter-based AF treatment featuring a 122-electrode array for rapid pulmonary vein isolation, high-definition mapping, and whole‑atrium ablation with a single catheter. The Globe System showed 78% freedom from atrial arrhythmia at 1 year in paroxysmal AF patients in the pivotal PULSAR study and reported 0% device-related primary safety events. The system is currently restricted to investigational use and has not been approved or cleared for commercial distribution. Kardium plans to use new funding to pursue regulatory approvals, expand manufacturing and production capacity, build a clinical support and commercial team, and run further clinical research for additional applications and indications. The company is privately held, was founded in 2007, and is headquartered in Vancouver, Canada. The recent financing positions Kardium to move toward a commercial launch later this year. Kardium develops the Globe Mapping and Ablation System, a single-catheter solution with a 122-electrode array and advanced software for rapid pulmonary vein isolation, high-definition mapping, and atrial ablation. The company says recent clinical data show freedom from atrial arrhythmia at one year of 84.2% in paroxysmal AF and 80% in persistent AF. Kardium raised US $104 million in a new financing to support completion of its PULSAR clinical study and to pursue regulatory approvals for the Globe System. The financing will also fund growth of manufacturing capacity and expansion of clinical support and commercial teams in preparation for commercial launch. Kardium is a privately held company founded in 2007 and headquartered in Vancouver, Canada. The Globe System remains restricted to investigational use and has not been approved or cleared for commercial distribution. Kardium has developed the Globe Mapping and Ablation System for the treatment of atrial fibrillation. The Globe System uses a sophisticated catheter with a 122-electrode array and advanced software to enable rapid pulmonary vein isolation, high-definition mapping, and the ability to ablate anywhere in the atrium with a single catheter. In the past six months the company secured CE mark approval, launched the Globe System in Europe, and deployed the Globe Positioning System (GPS) 3D mapping and navigation module. The new financing will be used to accelerate commercial growth across Europe and to conduct a clinical study for FDA approval of the Globe System. The financing will also fund clinical studies of a new pulsed field ablation (PFA) version of the Globe System following positive pre-clinical testing. Founded in 2007 and headquartered in Vancouver, Kardium plans to expand activity across European markets and advance its FDA submissions. Kardium develops the Globe® Mapping and Ablation System, a mapping and ablation solution for the treatment of atrial fibrillation. The Globe system pairs a sophisticated catheter with 122 electrodes and advanced software to enable rapid pulmonary vein isolation, high-resolution mapping, and the ability to ablate anywhere in the atrium. Kardium completed successful clinical testing of the Globe system in Switzerland and Germany and plans commercial sales in Europe in 2019. The company will also start a clinical study in the US this year. Kardium was founded in 2007 and is based in Vancouver, British Columbia. It announced a new, undisclosed financing led by funds and accounts advised by T. Rowe Price, which the company said will fund commercial activities in Europe and Canada and support US clinical testing.

Total raised

$467M

Funding rounds

4

Latest round

Equity

Latest activity

Jul 2025